Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PuriCore's endoscope disinfector

This article was originally published in Clinica

Executive Summary

PuriCore has received US FDA 510(k) market clearance for its Sterilox endoscopy high-level disinfectant system for use in reprocessing and disinfecting heat-sensitive medical instruments between patient procedures. The technology produces principally hypochlorous acid - an antimicrobial - from the electrolysis of a saline solution. Sterilox solutions are non-toxic and of no risk to patients, healthcare professionals, or the environment, claimed the company. "This is a big step in bringing Sterilox to the US endoscopy market, which is the largest in the world," said Greg Bosch, CEO of the Malvern, Pennsylvania firm, which anticipates installing its first US beta sites for Sterilox by the end of this year.

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel